ThunderStorm System will aid researchers in hereditary cancer testing using next-generation sequencing
LEXINGTON, Mass. – November 18, 2011 – RainDance Technologies, Inc., the Digital Biology™ Company, today announced that the British Columbia Cancer Agency has purchased the company’s new ThunderStorm™ System. RainDance’s ThunderStorm System is a fully-automated and walkaway high-throughput targeted sequencing solution that enables researchers to process up to 96 samples per run on a proven platform that generates higher-quality data faster than ever before.
Over the next two years, the British Columbia Cancer Agency aims to sequence a large number of samples from patients with hereditary predisposition to various cancers. This project will generate data that will be used as the basis to guide clinical management. The development of a high-throughput clinical next-generation sequencing pipeline is being supported by the Provincial Health Services Authority, BC Cancer Foundation and Genome BC.
“To truly understand the complete mutational spectrum of hereditary cancer-related genes, we require large-scale high-throughput approaches that generate reproducible sequence data with increased accuracy and greater coverage uniformity,” said Dr. Aly Karsan, Medical Director of the Centre for Clinical Diagnostic Genomics. “We were drawn to the RainDance ThunderStorm System because it offers an automated and high-throughput solution that allows us to screen large numbers of samples with high coverage and specificity.”
“The ThunderStorm System is well suited for cancer research projects that require the rapid, high-resolution analysis of specific genes of interest,” said Andy Watson, Chief Marketing Officer at RainDance Technologies. “Our ThunderStorm System is a cost-effective solution that enables the comprehensive interrogation and accurate classification of all variation contained in any region of the genome with increased accuracy, greater uniformity and more complete coverage than any other sequence enrichment method.”
Utilizing RainDance’s proprietary microdroplet-based technology, the ThunderStorm System simultaneously processes millions of individual single molecule PCR reactions by encapsulating each reaction in separate aqueous droplets. The system supports a range of targeted sequencing applications including: candidate gene lists, regions of association, signaling pathways and deep sequencing of heterogeneous tumor samples.
RainDance Technologies is showcasing the new ThunderStorm System at the Association for Molecular Pathology (AMP) 2011 Annual Meeting in Grapevine, Texas November 17-19, 2011. For more information, please visit RainDanceTech.com/amp2011.
About RainDance Technologies
RainDance Technologies is pioneering the use of high-throughput microdroplet-based analysis in human health and life science research. The company’s core RainStorm™ technology generates millions of discrete droplets that can encapsulate a single molecule, cell or reaction and be digitally analyzed and sorted one at a time. The power, precision and simplicity of microdroplets enable researchers to answer complex questions with unprecedented sensitivity and quantitation. The complete RainDance solution includes automated instrumentation, customizable bioinformatics and high-value consumables and reagents for applications including targeted next-generation DNA sequencing, methylation, digital PCR and single cell analysis. Based in Lexington, Massachusetts, the company supports scientists around the world through its international sales and support operations and a global network of distributors and service providers. For more information, please visit www.RainDanceTech.com.
RainDance, RainStorm, ThunderStorm, Digital Biology are trademarks of RainDance Technologies, Inc. All other brands may be trademarks of their respective holders.
The RainDance ThunderStorm System is for Research Use Only. Not for use in diagnostic procedures.